MedTrace Logo

LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma

NCT03101254 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-07-17

Study results available
· View outcomes & findings →

Summary

This research study is studying a combination of targeted therapies as a possible treatment for advanced melanoma that was found to have a BRAF V600E or BRAF V600K genetic mutation

The interventions involved in this study are:

* LY3022855
* Vemurafenib
* Cobimetinib

Conditions

Interventions

DRUG

LY3022855

LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor

DRUG

Vemurafenib

Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells

DRUG

Cobimetinib

Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Buchbinder, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-06
Primary Completion
2020-10-21
Completion
2020-11-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03101254 on ClinicalTrials.gov